Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1470
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Tasigna (Capsule)
|
| dailymed-instance:activeIng... | |
| dailymed-instance:boxedWarn... |
WARNING: QT PROLONGATION AND SUDDEN DEATHS: Tasigna prolongs the QT interval (5.2). Sudden deaths have been reported in patients receiving nilotinib (5.3). Tasigna should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome (4). Hypokalemia or hypomagnesemia must be corrected prior to Tasigna administration and should be periodically monitored (5.2). Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided (5.7). Patients should avoid food 2 hours before and 1 hour after taking dose (5.8). Use with caution in patients with hepatic impairment (5.9). ECGs should be obtained to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, as well as following any dose adjustments. (5.2, 5.3, 5.6, 5.12)
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:TITANIUM_DIOXIDE,
dailymed-ingredient:colloidal_silicon_dioxide,
dailymed-ingredient:crospovidone,
dailymed-ingredient:gelatin,
dailymed-ingredient:lactose_monohydrate,
dailymed-ingredient:magnesium_stearate,
dailymed-ingredient:polyoxamer_188,
dailymed-ingredient:red_iron_oxide,
dailymed-ingredient:yellow_iron_oxide
|
| dailymed-instance:genericMe... |
nilotinib
|
| dailymed-instance:fullName |
Tasigna (Capsule)
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Tasigna
|